Elevated levels of Interleukin (IL)-33 induce bone pathology but absence of IL-33 does not negatively impact normal bone homeostasis

Cytokine

Volumn 79, Issue , 2016, Pages 66-73

  Okragly, Angela J ^a   Hamang, Matthew J ^a   Pena, Emily A ^a   Baker, Hana E ^a   Bullock, Heather A ^a   Lucchesi, Jonathan ^a   Martin, Andrea P ^a   Ma, Y Linda ^a   Benschop, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Aging; Biomechanics; Bone; Genetic deficient mice; IL 33

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; GAMMA INTERFERON; INTERLEUKIN 33; INTERLEUKIN 6; OSTEOCALCIN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; CYTOKINE; IL33 PROTEIN, MOUSE; PEPTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DESTRUCTION; BONE MASS; BONE STRENGTH; CELL COUNT; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FEMUR; GENE OVEREXPRESSION; IN VIVO STUDY; KNOCKOUT MOUSE; LUMBAR VERTEBRA; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN INDUCTION; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOLOGY; GENETICS; MALE; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE DENSITY; BONE RESORPTION; COLLAGEN TYPE I; CYTOKINES; FEMALE; FEMUR; INTERLEUKIN-33; LUMBAR VERTEBRAE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOCLASTS; PEPTIDES;

EID: 84952903629     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.12.011     Document Type: Article

References (51)

1. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., Mcclanahan T.K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., Kastelein R.A. IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity 2005, 23(5):479-490.
2. Moussion C., Ortega N., Girard J.P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS ONE 2008, 3(10):e3331.
3. Lefrancais E., Cayrol C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur. Cytokine Netw. 2012, 23(4):120-127.
4. Chackerian A.A., Oldham E.R., Murphy E.E., Schmitz J., Pflanz S., Kastelein R.A. IL-1 Receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 2007, 179(4):2551-2555.
5. Kurowska-Stolarska M., Kewin P., Murphy G., Russo R.C., Stolarski B., Garcia C.C., Komai-Koma M., Pitman N., Li Y., Mckenzie A.N.J., Teixeira M.M., Liew F.Y., Xu D. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 2008, 181(7):4780-4790.
6. Palmer G., Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 2011, 7(6):321-329.
7. Yang Q., Li G., Zhu Y., Liu L., Chen E., Turnquist H., Zhang X., Finn O.J., Chen X., Lu B. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur. J. Immunol. 2011, 41(11):3351-3360.
8. Schneider E., Petit-Bertron A.-F., Bricard R., Levasseur M., Ramadan A., Girard J.-P., Herbelin A., Dy M. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J. Immunol. 2009, 183(6):3591-3597.
9. Pushparaj P.N., Tay H.K., H'ng S.C., Pitman N., Xu D., Mckenzie A., Liew F.Y., Melendez A.J. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. 2009, 106(24):9773-9778.
10. Stolarski B., Kurowska-Stolarska M., Kewin P., Xu D., Liew F.Y. IL-33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 2010, 185(6):3472-3480.
11. Koyasu S., Moro K. Innate Th2-type immune responses and the natural helper cell, a newly identified lymphocyte population. Curr. Opin. Allergy Clin. Immunol. 2011, 11(2):109-114.
12. Chang Y.J., Kim H.Y., Albacker L.A., Baumgarth N., Mckenzie A.N., Smith D.E., Dekruyff R.H., Umetsu D.T. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011, 12(7):631-638.
13. Rank M.A., Kobayashi T., Kozaki H., Bartemes K.R., Squillace D.L., Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 2009, 123(5):1047-1054.
14. Walsh N.C., Gravallese E.M. Bone remodeling in rheumatic disease: a question of balance. Immunol. Rev. 2010, 233(1):301-312.
15. Teitelbaum S.L. Bone Resorption by Osteoclasts. Science 2000, 289(5484):1504-1508.
16. Mcinnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007, 7(6):429-442.
17. Wei S., Kitaura H., Zhou P., Ross F.P., Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 2005, 115(2):282-290.
18. Zwerina J., Redlich K., Polzer K., Joosten L., Krönke G., Distler J., Hess A., Pundt N., Pap T., Hoffmann O., Gasser J., Scheinecker C., Smolen J.S., Van Den Berg W., Schett G. TNF-induced structural joint damage is mediated by IL-1. Proc. Natl. Acad. Sci. 2007, 104(28):11742-11747.
19. Horwood N.J., Udagawa N., Elliott J., Grail D., Okamura H., Kurimoto M., Dunn A.R., Martin T., Gillespie M.T. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 1998, 101(3):595-603.
20. Udagawa N., Horwood N.J., Elliott J., Mackay A., Owens J., Okamura H., Kurimoto M., Chambers T.J., Martin T.J., Gillespie M.T. Interleukin-18 (Interferon-γ-inducing Factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J. Exp. Med. 1997, 185(6):1005-1012.
21. Keller J., Catala-Lehnen P., Wintges K., Schulze J., Bickert T., Ito W., Horst A.K., Amling M., Schinke T. Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem. Biophys. Res. Commun. 2012, 417(1):217-222.
22. Anthony R.M., Kobayashi T., Wermeling F., Ravetch J.V. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 2011, 475(7354):110-113.
23. Zaiss M.M., Kurowska-Stolarska M., Böhm C., Gary R., Scholtysek C., Stolarski B., Reilly J., Kerr S., Millar N.L., Kamradt T., Mcinnes I.B., Fallon P.G., David J.-P., Liew F.Y., Schett G. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-α-mediated bone loss. J. Immunol. 2011, 186(11):6097-6105.
24. Xu D., Jiang H.-R., Kewin P., Li Y., Mu R., Fraser A.R., Pitman N., Kurowska-Stolarska M., Mckenzie A.N.J., Mcinnes I.B., Liew F.Y. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. 2008, 105(31):10913-10918.
25. Bessa J., Meyer C.A., De Vera Mudry M.C., Schlicht S., Smith S.H., Iglesias A., Cote-Sierra J. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J. Autoimmun. 2014, 55:33-41.
26. Palmer G., Talabot-Ayer D., Lamacchia C., Toy D., Seemayer C.A., Viatte S., Finckh A., Smith D.E., Gabay C. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009, 60(3):738-749.
27. Xiao W., Berta S.C., Lu M.M., Moscioni A.D., Tazelaar J., Wilson J.M. Adeno-associated virus as a vector for liver-directed gene therapy. J. Virol. 1998, 72(12):10222-10226.
28. Ma Y.F., Jee W.S.S., Ke H.Z., Lin B.Y., Liang X.G., Li M., Yamamoto N. Human parathyroid hormone-(1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats. J. Bone Miner. Res. 1995, 10(3):496-505.
29. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the asbmr histomorphometry nomenclature committee. J. Bone Miner. Res. 1987, 2(6):595-610.
30. Mun S.H., Ko N.Y., Kim H.S., Kim J.W., Kim Do K., Kim A.R., Lee S.H., Kim Y.G., Lee C.K., Lee S.H., Kim B.K., Beaven M.A., Kim Y.M., Choi W.S. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell. Mol. Life Sci. 2010, 67(22):3883-3892.
31. Saleh H., Eeles D., Hodge J.M., Nicholson G.C., Gu R., Pompolo S., Gillespie M.T., Quinn J.M. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology 2011, 152(5):1911-1922.
32. Schulze J., Bickert T., Beil F.T., Zaiss M.M., Albers J., Wintges K., Streichert T., Klaetschke K., Keller J., Hissnauer T.-N., Spiro A.S., Gessner A., Schett G., Amling M., Mckenzie A.N.J., Horst A.K., Schinke T. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J. Bone Miner. Res. 2011, 26(4):704-717.
33. Kiyomiya H., Ariyoshi W., Okinaga T., Kaneuji T., Mitsugi S., Sakurai T., Habu M., Yoshioka I., Tominaga K., Nishihara T. IL-33 inhibits RANKL-induced osteoclast formation through the regulation of Blimp-1 and IRF-8 expression. Biochem. Biophys. Res. Commun. 2015.
34. Eeles D.G., Hodge J.M., Singh P.P., Schuijers J.A., Grills B.L., Gillespie M.T., Myers D.E., Quinn J.M.W. Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitor. Mol. Cell. Endocrinol. 2015, 399:259-266.
35. Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanaka H., Ciliberto G., Rodan G.A., Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994, 13(5):1189-1196.
36. Talabot-Ayer D., Martin P., Vesin C., Seemayer C.A., Vigne S., Gabay C., Palmer G. Severe neutrophil-dominated inflammation and enhanced myelopoiesis in IL-33-overexpressing CMV/IL33 mice. J. Immunol. 2014.
37. Frost H.M. Bone "mass" and the "mechanostat": a proposal. Anat Rec 1987, 219(1):1-9.
38. Mindrescu C., Thorbecke G.J., Klein M.J., Vilcek J., Wisniewski H.G. Amelioration of collagen-induced arthritis in DBA/1J mice by recombinant TSG-6, a tumor necrosis factor/interleukin-1-inducible protein. Arthritis Rheum. 2000, 43(12):2668-2677.
39. Sasai M., Saeki Y., Ohshima S., Nishioka K., Mima T., Tanaka T., Katada Y., Yoshizaki K., Suemura M., Kishimoto T. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999, 42(8):1635-1643.
40. Tsuji F., Yoshimi M., Katsuta O., Takai M., Ishihara K., Aono H. Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice. BMC Musculoskelet. Disord. 2009, 10:23.
41. Zhou X., Hua X., Ding X., Bian Y., Wang X. Trichostatin differentially regulates Th1 and Th2 responses and alleviates rheumatoid arthritis in mice. J. Clin. Immunol. 2011, 31(3):395-405.
42. De Benedetti F., Alonzi T., Moretta A., Lazzaro D., Costa P., Poli V., Martini A., Ciliberto G., Fattori E. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 1997, 99(4):643-650.
43. De Benedetti F., Rucci N., Del Fattore A., Peruzzi B., Paro R., Longo M., Vivarelli M., Muratori F., Berni S., Ballanti P., Ferrari S., Teti A. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006, 54(11):3551-3563.
44. Mori T., Miyamoto T., Yoshida H., Asakawa M., Kawasumi M., Kobayashi T., Morioka H., Chiba K., Toyama Y., Yoshimura A. IL-1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int. Immunol. 2011, 23(11):701-712.
45. Gao Y., Grassi F., Ryan M.R., Terauchi M., Page K., Yang X., Weitzmann M.N., Pacifici R. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest. 2007, 117(1):122-132.
46. Braun T., Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res. Ther. 2011, 13(4):235.
47. Kapoor M., Martel-Pelletier J., Lajeunesse D., Pelletier J.P., Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 2011, 7(1):33-42.
48. Baum R., Gravallese E.M. Impact of inflammation on the osteoblast in rheumatic diseases. Curr. Osteoporos. Rep. 2014, 12(1):9-16.
49. Mine Y., Makihira S., Yamaguchi Y., Tanaka H., Nikawa H. Involvement of ERK and p38 MAPK pathways on Interleukin-33-induced RANKL expression in osteoblastic cells. Cell. Biol. Int. 2014, 38(5):655-662.
50. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., Qvist P., Delmas P.D., Foged N.T., Delaisse J.M. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J. Bone Miner. Res. 2003, 18(5):859-867.
51. Martin P., Talabot-Ayer D., Seemayer C.A., Vigne S., Lamacchia C., Rodriguez E., Finckh A., Smith D.E., Gabay C., Palmer G. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res. Ther. 2013, 15(1). R13-R.